Defining the Correlates of Bactericidal Immunity in Tuberculosis
定义结核病杀菌免疫的相关性
基本信息
- 批准号:8031491
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-01-01 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAnimalsAntigensAreaB-LymphocytesCD4 Positive T LymphocytesCD8B1 geneCell surfaceCellsCessation of lifeCharacteristicsCommunicable DiseasesCountryDevelopmentEngineeringEnvironmentEscherichia coliExtreme drug resistant tuberculosisFundingGenesGoalsHandImmune SeraImmune systemImmunityImmunizationImmunotherapeutic agentInterventionLaboratoriesLicensingMedicineMethodsMorbidity - disease rateMusMycobacterium smegmatisMycobacterium tuberculosisMycobacterium tuberculosis antigensOrganismPharmaceutical PreparationsPhenotypePlanetsPopulationPreventionProductionProteinsProtocols documentationRecombinant ProteinsRecombinantsResearchSpecificitySterilizationSystemT cell responseT memory cellT-Cell Immunologic SpecificityT-LymphocyteTissuesTransgenic OrganismsTuberculosisTuberculosis VaccinesVaccinesVirulentWorkbactericidal immunitybactericidecollegecytokinedesign and constructiondirect applicationfootglobal healthimprovedkillingsmemory CD4 T lymphocytemortalitymycobacterialnovelnovel strategiesprogramsresponsetooltuberculosis immunityvaccination against tuberculosis
项目摘要
DESCRIPTION (provided by applicant): Tuberculosis remains one of the most significant global causes of morbidity and mortality from infectious disease, and an effective vaccine for controlling Mycobacterium tuberculosis (Mtb) has yet to be found. Well established correlates of vaccine induced protection against Mtb have not been established, and it remains to be shown that the immune system is capable of achieving high levels of bactericidal immunity against this organism. Along with our colleagues in the tuberculosis research group at Einstein, we have recently produced and characterized a genetically engineered form of the rapidly growing nonpathogenic M. smegmatis that can induce an extraordinary and unprecedented level of protective immunity in mice against Mtb. Initial studies show that mice immunized with this M. smegmatis strain, which we designate IKE+, can respond to challenges by virulent Mtb with rapid induction of a high level of bactericidal immunity. This is associated with unprecendented reductions in tissue bacterial levels, and in some cases even complete sterilization of tissues with apparent cure of tuberculosis. Preliminary adoptive transfer studies show that this immunity is dependent on a population of memory CD4+ T cells, which are able to transfer a significant level of the bactericidal response to naove animals. Furthermore, the induction of this population of CD4+ T cells appears to be dependent on the presence of B cells in the immunizing environment. These findings define a new experimental system in which to seek correlates of bactericidal immunity against M. tuberculosis, which we will use to identify the characteristics of the specific T cell populations that are capable of inducing the remarkable anti-mycobacterial responses. In this two year project, we propose to identify the phenotype and antigen specificities of the relevant T cell populations, and extensively characterize their functional activities with respect to production of key cytokines and other effector molecules. These studies are likely to reveal previously unexplored mechanisms by which the immune system can control and eliminate Mtb, and have potentially major implications for development of tuberculosis vaccines.
PUBLIC HEALTH RELEVANCE: Tuberculosis remains one of the most important global causes of morbidity and mortality from infectious disease. This proposal is an integral component of a program that aims to understand in greater detail the mechanisms by which the immune system can be made to recognize and kill Mycobacterium tuberculosis following specific immunization with novel experimental vaccines. The goal of the research is to establish principles that will enable the design and construction of better vaccines for the prevention of tuberculosis.
描述(申请人提供):结核病仍然是全球传染病发病率和死亡率最重要的原因之一,并且尚未发现用于控制结核分枝杆菌(Mtb)的有效疫苗。并且免疫系统能够实现针对该生物体的高水平的杀菌免疫仍有待证明。沿着我们在爱因斯坦的结核病研究小组的同事,我们最近已经生产并鉴定了一种快速生长的非致病性M.在小鼠中可诱导针对Mtb的非凡和前所未有的保护性免疫水平的丝霉亲和素。初步研究表明,用这种M.我们将其命名为IKE+的耻垢病菌株可以快速诱导高水平的杀菌免疫来应答毒性Mtb的攻击。这与组织细菌水平的前所未有的降低有关,在某些情况下,甚至组织完全灭菌,结核病明显治愈。初步的过继转移研究表明,这种免疫力依赖于记忆性CD4 + T细胞群,它们能够将显著水平的杀菌反应转移给新生动物。此外,该CD4 + T细胞群的诱导似乎依赖于免疫环境中B细胞的存在。这些发现定义了一个新的实验系统,在其中寻找针对M.结核病,我们将使用它来确定能够诱导显着的抗分枝杆菌反应的特定T细胞群的特征。在这个为期两年的项目中,我们建议确定相关T细胞群体的表型和抗原特异性,并广泛表征其在关键细胞因子和其他效应分子产生方面的功能活性。这些研究可能揭示免疫系统控制和消除结核分枝杆菌的机制,并对结核病疫苗的开发具有潜在的重大意义。
公共卫生相关性:结核病仍然是全球传染病发病和死亡的最重要原因之一。该提案是一个计划的一个组成部分,该计划旨在更详细地了解免疫系统在使用新型实验疫苗进行特异性免疫后识别和杀死结核分枝杆菌的机制。这项研究的目标是建立原则,使设计和建设更好的疫苗,以预防结核病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven A Porcelli其他文献
Steven A Porcelli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven A Porcelli', 18)}}的其他基金
Bigfoot Multispectral High Speed Fluorescence Activated Cell Sorter
Bigfoot 多光谱高速荧光激活细胞分选仪
- 批准号:
10414835 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
- 批准号:
8871648 - 财政年份:2015
- 资助金额:
$ 24.9万 - 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
- 批准号:
8230473 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
- 批准号:
8626351 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
- 批准号:
8049854 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
- 批准号:
8083413 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 24.9万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 24.9万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 24.9万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别: